HOPE-3 was designed to assess if reducing BP and/or LDL-C would reduce cardiovascular events in study participants at intermediate risk with no prior cardiovascular events.
The association between stroke and obesity in adolescence was examined in a population-based study.
Researchers sought to identify and analyze risk factors for thrombosis in adolescent girls receiving hormonal therapy.
Diabetes is associated with increased risk of vascular conditions, such as ischemic heart disease, stroke, renal, and neuropathic complications. In this featured study, researchers examine how the cause of mortality in diabetes has changed over time.
At the 2021 International Stroke Conference, researchers presented their findings on stroke among men with COVID-19 and high comorbidity burden.
The approval was based on data from the phase 3 ODYSSEY HoFH trial, which evaluated Praluent in 69 adults with HoFH who were on other LDL-C-lowering therapies.
Statins were associated with a reduction in mortality but there was no significant difference in the composite end point with fenofibrates alone or in combination with statins.
Increased mortality risks were limited to the first post-HT year because increases in risks markedly decreased when the follow-up time was extended over more than 1 year.
Increases in BMI z-score between 7 and 13 years of age increase a person’s risk of ischemic stroke in early adulthood.
Hyperglycemia treatment was left to physician’s discretion.
